SAN JOSE, Calif., April 23, 2018 -- According to the latest report published by Credence Research, Inc. “Post-Traumatic Stress Disorder Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.
Market Insights
Post-traumatic stress disorder (PTSD) therapeutics market projected to an extent by US$ 10,679.5 Mn by 2026 with a CAGR of 4.5% throughout the forecast period from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market. Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.
As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals. The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.
Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.
Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period. However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.
Browse Full Report With TOC, Figures And Tables @ http://www.credenceresearch.com/report/post-traumatic-stress-disorder-therapeutics-market
Related Reports:
Cytomegalovirus (CMV) Infection Treatment Market
Acquired Hemophilia Treatment Market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: +1-800-361-8290
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch
G+ @ https://plus.google.com/+Credenceresearch


Capital One Says AML Review Led to Closure of Trump Organization Accounts
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Japan Earthquake Disrupts Auto and Chip Supply Chains
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 



